Profile data is unavailable for this security.
About the company
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
- Revenue in USD (TTM)234.04m
- Net income in USD-323.99m
- Incorporated1999
- Employees534.00
- LocationRevance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
- Phone+1 (615) 724-7755
- Fax+1 (302) 655-5049
- Websitehttps://www.revance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nature's Sunshine Products Inc | 445.32m | 15.08m | 372.05m | 814.00 | 25.63 | 2.42 | 13.18 | 0.8355 | 0.7715 | 0.7715 | 22.78 | 8.16 | 1.86 | 1.84 | 38.84 | 547,076.20 | 6.85 | 6.57 | 10.02 | 9.41 | 72.11 | 72.69 | 3.69 | 3.74 | 1.29 | -- | 0.00 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Alto Neuroscience Inc | 0.00 | -36.31m | 373.15m | 63.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | 2.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1238 | -- | -- | -- | -31.02 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 170.28m | -225.25m | 374.34m | 709.00 | -- | 1.21 | -- | 2.20 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Anika Therapeutics Inc | 166.66m | -82.67m | 377.59m | 357.00 | -- | 1.78 | -- | 2.27 | -5.64 | -5.64 | 11.37 | 14.48 | 0.5378 | 1.48 | 4.72 | 466,840.30 | -26.68 | -5.41 | -29.48 | -5.87 | 61.85 | 60.70 | -49.60 | -12.60 | 3.76 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| PepGen Inc | 0.00 | -78.63m | 379.19m | 64.00 | -- | 2.58 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Revance Therapeutics Inc | 234.04m | -323.99m | 381.43m | 534.00 | -- | -- | -- | 1.63 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Tourmaline Bio Inc | 0.00 | -42.12m | 387.01m | 44.00 | -- | 1.50 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Mersana Therapeutics Inc | 36.86m | -171.67m | 389.38m | 123.00 | -- | 10.50 | -- | 10.57 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 393.25m | 862.00 | 81.07 | 1.40 | 19.36 | 0.9079 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 393.72m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| iTeos Therapeutics Inc | 12.60m | -112.64m | 393.92m | 157.00 | -- | 0.6847 | -- | 31.28 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Biomea Fusion Inc | 0.00 | -117.26m | 394.07m | 103.00 | -- | 2.33 | -- | -- | -3.46 | -3.46 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -71.23 | -- | -81.63 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -209.96m | 394.11m | 284.00 | -- | 0.9349 | -- | -- | -3.16 | -3.16 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -34.66 | -26.12 | -36.63 | -27.31 | -- | -- | -- | -- | -- | -- | 0.1436 | -- | -- | -- | -47.65 | -- | 75.59 | -- |
| Esperion Therapeutics Inc | 116.33m | -209.25m | 395.85m | 240.00 | -- | -- | -- | 3.40 | -2.11 | -2.11 | 1.13 | -3.85 | 0.5128 | 0.8583 | 2.83 | 484,725.00 | -92.23 | -69.45 | -203.94 | -101.81 | 62.81 | -- | -179.87 | -147.44 | 0.867 | -2.85 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Cibus Inc | 1.82m | -267.63m | 396.00m | 183.00 | -- | 1.12 | -- | 217.94 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
Data as of Apr 24 2024. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD
47.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 11.94m | 11.46% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 6.72m | 6.45% |
| GIC Pte Ltd. (Investment Management)as of 08 Mar 2024 | 5.83m | 5.59% |
| Palo Alto Investors LPas of 31 Dec 2023 | 5.24m | 5.03% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.83m | 4.64% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 4.71m | 4.52% |
| Polar Capital LLPas of 31 Dec 2023 | 3.17m | 3.04% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 2.56m | 2.46% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.52m | 2.42% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.92m | 1.85% |
More ▼
Data from 31 Dec 2023 - 15 Apr 2024Source: FactSet Research Systems Inc.
